🇺🇸 FDA
Pipeline program

brinzolamide 1%/brimonidine 0.2% fixed combination

CQVJ499A2404

Approved small_molecule completed

Quick answer

brinzolamide 1%/brimonidine 0.2% fixed combination for Glaucoma is a Approved program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Glaucoma
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials